# Retrospective Analysis of Clinical Features in 101 Death Cases with COVID-19

#### **Authors:**

Hua Fan<sup>1\*</sup>;Lin Zhang<sup>1\*</sup>;Bin Huang<sup>2\*</sup>;Muxin Zhu<sup>3\*</sup>;Yong Zhou<sup>3\*</sup>;Huan Zhang<sup>1</sup>;Xiaogen Tao<sup>1</sup>;Shaohui Cheng<sup>1</sup>;Wenhu Yu<sup>4</sup>†;Liping Zhu<sup>3</sup>†;Jian Chen<sup>1</sup>†

#### **Affiliations:**

<sup>1</sup>Department of Intensive Care Medicine, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, China

<sup>2</sup>Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, China

<sup>3</sup>Infection Disease Department, Wuhan Jinyintan Hospital, Wuhan, Hubei, 430023, China;

<sup>4</sup>Department of Intensive Care Medicine, Xiantao First People's Hospital, Xiantao, Hubei, 433000, China;

Hua Fan ;Lin Zhang ;Bin Huang ; Muxin Zhu;Yong Zhou have contributed equally to this work

\*Contributed equally †Joint corresponding authors

#### **Corresponding Author:**

т.				
Jia	n	ויו	2	าก
JIA	11 '	v	10	7

No.1 Tiane Road, Shu Shan District, The First Affiliated Hospital of USTC,

Hefei, Anhui 230036, China

Tel: +86 13637082683

Email: chenjian214891@163.com

Wenhu Yu

No. 29 Mianzhou road, Xiantao, Hubei 433000, China

Tel:+8618972947069

Email:402956986@qq.com

Liping Zhu

Wuhan Jinyintan Hospital, No.1 Yintan Road,Dongxihu District, Wuhan,Hu bei430023,China

Tel:+8615926216455

Email:21096601@qq.com

#### Abstract

**Background** The illness progress of partial patient of COVID-19 is rapid and the mortality rate is high.we aim to describe the clinical features in death cases with COVID-19.

**Methods** In this single center, observational study, We recruited all Death Cases with COVID-19 from Dec 30, 2019 to Feb 16, 2020 in Intensive care unit of Wuhan Jinyintan Hospital.Demographics, basic diseases, X-ray/CT results, possible therapy strategies and test results when their entrance into admission, ICU and 48 h before death were collected and analyzed.

**Results** This study involved 101 COVID-19 dead cases in Intensive care unit of Wuhan Jinyintan Hospital.47 patients went directly to the ICU because of critical condition, and

54 patients were transferred to ICU with aggravated condition.57 (56.44%) were laboratory confirmed by RT-PCR, and 44 (43.6%) were consistent with clinical diagnostic criteria. The cases included 64 males and 37 females with average age of 65.46 years (SD 9.74). The blood type distribution was significantly different, with type A 44.44%, type B 29.29%, type AB 8.08% and type O 18.19%. The clinical manifestations of new coronavirus pneumonia are non-specific, the common symptom was fever (91 [90.10%] of 101 patients), Cough (69[68.32%]) and dyspnea (75[74.26%]). Neutrophils, PCT, CRP,IL-6,D-dimer gradually increased as time went on. Myocardial enzymes were abnormal in most patients at admission, with the progress of the disease, myocardial indicators significantly increased.61(60.40%) damage were used antiviral drugs,59(58.42%) used glucocorticoids, 63.37% used intravenous immunoglobulins, and 44.55% used thymosin preparations. All patients received antibiotic treatment, 63(62.38%) used restricted antibiotics, 23(22.78%) used antifungal drugs.84(83.17%) used non-invasive ventilator or high-flow oxygen therapy equipment, and 76.24% used invasive mechanical ventilation. 7 patients were treated with ECMO and 8 patients were treated with CRRT. The median time from ARDS to invasive mechanical ventilation was 3.00 days(IQR 0.00-6.00). The duration of invasive mechanical ventilation was 5 days (IQR2.00-8.00).

**Conclusions** Critical COVID-19 can cause fatal respiratory distress syndrome and multiple organ failure with high mortality rate. Heart may be the earliest damaged organ except the lungs. Secondary infection in the later period is worthy of attention.

# 1. INTRODUCTION

In December 2019, viral pneumonia outbreaks caused by coronavirus occurred in Wuhan, China, and spread rapidly worldwide<sup>[1-5]</sup>. The illness progress of partial patient is rapid and the mortality rate is 3.4%. By 5<sup>th</sup> March, 2020, the cumulative number of infections wordwild was 95,333, of which 3,282 died<sup>[5]</sup>. In 30th January, 2020, the World

Health Organization issued a global warning about the highly contagious virus<sup>[6]</sup>, which was named as Coronavirus disease 2019 (COVID-19) in 11<sup>th</sup> February<sup>[7]</sup>. Current studies<sup>[8-10]</sup> demonstrate the laboratory and clinical features that COVID-19 often occurs in elderly men with basic diseases. In early stage, fever and dry cough with reduced lymphocytes are the major symptoms, which develop into fatal respiratory distress syndrome and multiple organ failure in the late stage.

However, there are few studies on the clinical characteristics of death cases due to the small sample size. To understand the clinical characteristics, a retrospective analysis of clinical features in 101 death cases in Wuhan Jinyintan Hospital is carried out.

#### 2. METHODS

#### 2.1. Study Population

This study collected Death Cases with COVID-19 from Dec 30, 2019 to Feb 16, 2020 in Intensive care unit(ICU) of Wuhan Jinyintan Hospital. Wuhan Jinyintan Hospital is an infectious disease hospital, which is prescribed by Chinese government as one of the first designated treatment units for patients with the disease. The diagnosis of confirmed cases and clinical cases is in line with Diagnosis and Treatment of Novel Coronavirus Pneumonia (trial version 5)<sup>[11]</sup>. The confirmed cases are those who have pathogenic evidence, positive RT-PCR or highly homologous gene sequencing with known coronavirus. The clinical cases are those who have epidemic history, or who have no definite epidemic history but have clinical symptoms and imaging characteristics. Epidemic history includes that within 14 days somebody has travelling history in Wuhan

and surrounding areas, been exposed to other infections, communicated with patients with fever or respiratory symptoms from Wuhan and surrounding areas or from case-reporting communities, or clustering onset. The clinical symptoms include fever or respiratory symptoms, and decreased lymphocyte with normal or decrease leukocyte in the early stage.

This study is approved by the Ethics Committee of Wuhan Jinyintan Hospital Approval, and all relevant personnel exempt from informed consent due to the particularity of the disease outbreak.

#### 2.2. Data Collection

The retrospective analysis is based on the case reports, nursing records, test results, and imaging results. Data include demographics, basic diseases, X-ray/CT results, possible therapy strategies and test results when their entrance into admission, ICU and 48 h before death. The therapy strategy represents antiviral treatment, antibacterial treatment, corticosteroid treatment, immunotherapy, and respiratory therapy. The onset time is defined as the day symptom appears. Records begins from onset to admission, admission to ICU, ICU periods, and onset to death.

#### 2.3. Statistical Analysis

We compared the differences in epidemiologic, clinical, and laboratory measures between patients who had died due to infection by COVID-19 at onset to admission, admission to ICU and 48h before death. We present continuous measurements as mean (SD) if they are normally distributed or median (IQR) if they are not, and categorical

variables were described as frequency rates and percentages(%). For laboratory results, we also assessed whether the measurements were outside the normal range. We used SPSS (version 24.0) for all analyses.

#### 3. RESULTS

### 3.1. Demographics

By Feb 16, 2020, this study involved 101 COVID-19 dead cases in Intensive care unit of Wuhan Jinyintan Hospital, of which 57 (56.44%) patients were laboratory confirmed by RT-PCR, and 44 (43.6%) patients were consistent with clinical diagnostic criteria. In the death cases, 47 patients went directly to the ICU because of critical condition, and 54 patients were transferred to ICU with aggravated condition. All cases died in the end. Among them, 1 patients died with the symptom of acute coronary artery, while the rest of them died with the symptom of respiratory failure and multiple organ failure caused by COVID-19. The cases included 64 males and 37 females with the age range of 24-83 and average age of 65.46 years (SD 9.74). The majority had basic diseases with hypertension 42.57%, diabetes 22.77%, neurological disease 9.90%, malignant tumor 4.95%, and respiratory disease 4.95%. Cases combined with more than two basic diseases reached 25.74%. In detail, 10 patients had contact history with South China Seafood Market, and 10 patients had close contact history with infections. The blood type distribution was significantly different, with type A 44.44%, type B 29.29%, type AB 8.08% and type O 18.19%. The median time from onset to hospital was 11.00 days ( IQR8.00-13.50 ) . The median time from onset to death was 21.00 days ( IQR17.00-27.5 ) (Table 1) .

#### 3.2. Clinical Features

The relative frequencies of all reported symptoms at the time of admission are shown in Table 2. The most common symptom was fever (91 [90.10%] of 101 patients), but most patients dropped to normal temperature after admission 1-3 days, which may be related to hormone use. Cough (69 [68.32%]) and dyspnea (75 [74.26%]) were also common symptoms. 31(30.69%) patients had sputum symptoms in the early stage with white sputum, and 3 patients showed yellowish purulent sputum. 50(49.50%) patients showed Acute respiratory distress syndrome(ARDS) at the time of admission, and the median time from onset to ARDS was 12 days(IQR9.00-14.00).Other common symptoms included myalgia, general weakness, dizziness, headache, nausea and vomiting, among which 86(85.15%) patients had more than two symptoms.21(20.79%) patients had no respiratory symptoms, and 7(6.93%) patients initially appeared gastrointestinal symptoms such as nausea and vomiting. Distinctive from SARS, only 2 patients with COVID-19 had diarrhea.

#### 3.3. Radiographic Findings

Most of patients (99 [98.02%] of 101 patients) had abnormal lung imaging at the time of initial admission, 6(5.94%) patients had single-lung disease, and 93(92.08%) patients had double-lung disease. The disease initially showed scattered plaque-like ground glass in the lung. Dynamic imaging showed progressive multi-spot patchy

shadows in both lungs. Pneumothorax or subcutaneous emphysema occurred in 3 (2.97%) patients.

## 3.4. Laboratory Findings

Blood routine, biochemical reports and inflammation of cases when their entrance into admission, ICU and 48h before death were collected. Most patients showed increased leukocytes, neutrophils, decreased lymphocytes and time of consultation.Their inflammatory indicators such neutrophils, as Procalcitonin(PCT), C-reactive protein(CRP), and Interleukin-6(IL-6) gradually increased as time went on. It was found that patient's platelets(PLT) decreased, D-dimer and Prothrombin time(PT) increased correspondingly during disease progression via dynamic analysis of coagulation-related indicators. Myocardial enzymes were abnormal in most patients at admission(83 [82.18%] of 101 patients). With the progress of the disease, myocardial damage indicators were significantly increased. It also indicated that there was a high proportion of myocardial damage in the early stage. This study also found that liver and kidney damage were not significant at the time of admission and when transferred to ICU, and it significantly turned worse 48h before death. Experiment data can be seen in Table 3-5.

#### 3.5. Treatment

For all patients, 97 patients were transferred to Jinyintan Hospital due to laboratory diagnosis or exacerbation after treatment in other hospitals. All patients were treated in isolation. Among them, 61(60.40%) used antiviral drugs, including Oseltamivir, Ribavirin,

Lopinavir, Ritonavir, Ganciclovir, Interferon, etc. 59(58.42%) patients used glucocorticoids, 64(63.37%) patients used intravenous immunoglobulins, and 45(44.55%) patients used thymosin preparations. All patients received antibiotic treatment, including cephalosporins and quinolones, etc.,More than half of patients used restricted antibiotics(63 [62.38%] of 101 patients), including carbapenems, linezolid, tigecycline, etc., due to repeated rise in body temperature or wave in inflammation indicators. 23(22.78%) patients used antifungal drugs.

All patients received oxygen therapy. 84(83.17%) used non-invasive ventilator or high-flow oxygen therapy equipment, and 77(76.24%) used invasive mechanical ventilation. The median time from ARDS to invasive mechanical ventilation was 3.00 days(IQR0.00-6.00), of which 21 patients were intubated 2 days before death. The duration of invasive mechanical ventilation was 1–31 days (median 5 days [IQR2.00-8.00]). 7 patients were treated with ECMO and 8 patients were treated with CRRT.

#### 4. DISCUSSION

Our study reported the clinical characteristics of 101 deaths from COVID-19. As far as we know, this is the largest sample among the research reports on the clinical characteristics of dead patients. Although previous studies included some deaths, the number of cases were less.

Up to 5<sup>th</sup> March, 2020, the cumulative number of infected people wordwild was 95,333, and the number of death was 3,282. The mortality rate was as high as 3.4%,

which is much higher than that of general pneumonia. Among the 101 deaths, male is significantly higher than female, and the proportion of elderly patients with basic diseases is relatively high. The average age of death patients in this study was significantly higher than previous studies. In the study, we found the blood group composition of death patients (A-42.57%, B-30.69%, O-17.82%, AB-8.91%) was different from that of Han population in Wuhan<sup>[12]</sup>. Type O was relatively low, and Type A was relatively high. The mechanism which caused this is still unclear. ABO blood group antigen substances are widely distributed in the human respiratory system, digestive tract system, and reproductive system<sup>[13]</sup>. Previous research has shown that ABO blood group are related to the onset and spread of various diseases because the blood group antigens may participate in virus infection as receptor<sup>[14-15]</sup>. In the study of various susceptible genes in SARS-CoV, individuals in the blood group O have a lower infection rate<sup>[16]</sup>. Guillon et al. found that A antibody can provide protection by inhibiting interaction between the virus and ACE2 receptor<sup>[17]</sup>. However, the higher proportion of patients with type A blood is temporarily unclear and the reason may be the lack of antibody A protection. Further research is need to explore the specific mechanism.

The clinical manifestations of COVID-19 are non-specific, which is consistent with previous studies<sup>[10]</sup>, the most common symptom is fever. However, not all patients had fever and 10(9.90%) cases of patients were not detected fever in the onset. Moreover, 21(20.79%) of the patients had no respiratory symptoms when they the disease started, and symptoms such as fever and chest tightness gradually occurred as the disease progressed. Therefore, the delay of fever and respiratory symptoms may affect the early

recognition probably.

The mortality of critically ill COVID-19 patients is high, but its mechanism is not clear at present, and it may be related to the virus-induced acute lung injury, inflammatory factor storm, multiple organ damage and secondary nosocomial infections. We collected Laboratory examination results of patients at admission, at the time of transfer to the ICU, and at 48h before death and found that 71(70.30%) of patients had an elevated level of IL-6 when they were admitted to hospital, and it gradually increased as disease progressed and was as high as 26.21pg/mL(IQR11.68-205.92) 48h before death, which is significantly higher than results reported by Chen et al<sup>[9]</sup>. Considering that these patients have severe inflammatory reaction. We found that 23(22.78%) of patients had abnormal coagulation function at admission, which is mainly manifested as increased D-D and a sudden deterioration, we need to be vigilant about the presence of pulmonary thromboembolism after micro-thrombosis in the lungs or deep vein thrombosis. For hypercoagulable patients without contraindications, reasonable anticoagulant therapy is a possible strategy.

It has been reported that the 2019 novel coronavirus(2019-nCov) can damage function of organs such as the lungs, kidneys, heart, liver, etc., but there was no relevant description of the involvement sequence of other organs except lung. We collected indicators of organ damage when patients were admitted to the hospital and found that Most of patients had myocardial damage , of which 32 patients were only complicated with myocardial damage.2019-nCov and 2003-SARS both belong to the  $\beta$  coronavirus genus, and angiotensin-converting enzyme 2 (ACE2) has been confirmed as a common

pathogenic target<sup>[19].</sup> 31% of ICU patients were detected significant abnormalities in Troponin I(TNI) in Huang's research<sup>[8]</sup>. This study found that TNI was significantly higher in the ICU or before death, compared with when they were admitted to hospital. Further analysis revealed that patients who enter hospital with elevated troponin survive a faster progress from paroxysm to ICU and a shorter overall duration. The duration will be even shorter if increase in TNI accompanied. The above results suggest that heart is a potential target for 2019-nCOV and it impacts the disease process, so we need to monitor and evaluate heart damage early while focusing on lung injury.

We found that as the disease progressed, patients' leukocytes, neutrophils, PCT, CRP, etc. gradually increased, while lymphocytes increased again after the decline, and some patients experienced a drop in body temperature and then increased or continued temperature fluctuations. These indicators do not fully meet the characteristics of viral infections. It is necessary to be alert to that patients who may have bacterial infections. The sputum culture results also proved that some patients had bacterial and fungal infections, among which *Klebsiella pneumoniae*, *Acinetobacter baumannii* and *Candida albicans* were most common bacteria. Secondary bacterial and fungal infections in patients may be related to low immune function, severe lack of medical resources and unsmooth sputum drainage. In addition, we need to be aware that clinical manifestations of bacterial or fungal infections for critically ill patients may be not typical because their immune function is extremely low and most of them are in hormone therapy. However, the disease progress is rapid and can exacerbate in a short period of time leading to death. Therefore, it is necessary to pay close attention to changes in patient temperature,

laboratory indicators, imaging indicators and airway secretion characteristics. Prevention and control of nosocomial infections also need to be strengthened.

In terms of treatment, usage of antiviral drugs and hormones and related course is still controversial. In this study, 60.40% of patients used antiviral drugs, 58.42% patients used glucocorticoids, and the treatment course was mostly 3-5 days. All patients received antibiotic treatment including cephalosporins and quinolones. More than half of patients used restricted antibiotics due to fluctuations in body temperature or inflammation indicators. Mechanical ventilation is the main supportive treatment for critically ill patients, but the overall survival time of patients after invasive mechanical ventilation was short(median 5 days [IQR2.00-8.00]), and most patients did not benefit significantly from invasive mechanical ventilation. Most patients had suffered multiple organ failure caused by severe hypoxia before invasive mechanical ventilation. Therefore, for critical patients, early invasive mechanical ventilation treatment should be in consideration.

This study has some limitations. Only the critically death patients include in the group, and there is no comparison between the improvement groups. The sample size can be increased in further research for prospective case-control study. The blood group composition of patients cannot be statistically analyzed and whether the blood group difference is related to the susceptibility and mortality needs further study.

#### 5. CONCLUSION

Critical COVID-19 can cause fatal respiratory distress syndrome and multiple organ failure with high mortality rate. Heart may be the earliest damaged organ except the lungs.

Se	condary infection in the later period is worthy of attention.		
_			
		Patients/days(n=101)	

Age,years	
Mean(SD)	65.46±9.74
Range	24-83
≤44	3 ( 3.00% )
45-59	19 ( 18.80% )
60-74	60 ( 59.40% )
≥75	19 ( 18.80% )
Sex	
Female	37 ( 37.00% )
Male	64 ( 64.00% )
Days of illness	
Days from onset to admission	11.00 ( 8.00-13.50 )
Days in general ward	0.00 ( 0.00-4.00 )
Days in ICU	8.00 ( 4.00-11.00 )
Days from onset to death	21.00 ( 17.00-27.50 )
Blood group	
A	44(44.44%)
В	29(29.29%)

AB	8(8.08%)
O	18(18.19%)
Exposure history	
Long-term exposure history Huanan seafood market	7(6.93%)
Short-term exposure history Huanan seafood market	3(2.97%)
Casual contact with a patient with COVID-19	10(9.90%)
Positive RT-PCR	57(56.44%)
Chronic medical illness	
Cardiovascular and cerebrovascular diseaset	49 ( 48.51% )
Endocrine system diseaset	23 ( 22.77% )
Malignant tumour	5 ( 4.95% )
Nervous system disease	10 ( 9.90% )
Respiratory system disease	5 ( 4.95% )

Values are numbers (percentages) or Medium (IQR) unless stated otherwise. Percentages do not total up to 100% owing to missing data.

	Patients (n=101)
Symptoms at admission	
Fever	91 ( 90.10% )
Highest temperature , $\Box$	
<37.3	10 ( 9.90% )
37.3-38	33 ( 32.67% )
38.1-39	42 ( 41.58% )
>39	16 ( 15.84% )
Nonproductive Cough	38 ( 37.62% )
Productive Cough	31 ( 30.69% )
Hemoptysis	3 ( 2.97% )
Sore Throat	6 ( 5.94% )
Dyspnea	75 ( 74.26% )
Chills	13 ( 12.87% )
Myalgia	9 ( 8.91% )
Diarrhea	2 ( 1.98% )

Malaise	21 ( 20.79% )
Nausea or Vomiting	7 ( 6.93% )
Dizziness	7 ( 6.93% )
Headache	3 ( 2.97% )
Treatment	
Invasive Mechanical ventilation	79 ( 78.22% )
Non-invasive ventilation or high-flow nasal cannula	84 ( 83.17% )
Camala	
ECMO	7 ( 6.93% )
CRRT	8 ( 7.92% )
Antiviral treatment	61 ( 60.40% )
Antibiotic treatment	101 ( 100% )
Antifungal treatment	23 ( 22.77% )
Glucocorticoids	59 ( 58.42% )
Intravenous immunoglobulin therapy	64 ( 63.37% )
Thymosin	45 ( 44.55% )

CRRT=continuous renal replacement therapy. ECMO=Extracorporeal Membrane Oxygenation

Values are numbers (percentages) unless stated otherwise.

Table3. Dynamic Profile of Laboratory Findings in patients with COVID-19

	At admission(N=54)	Admission	to	48h	before
		ICU(N=101)		death(N=101)	
White blood cell count					
$Leucocytes (\times 10 \square per L; normal range  3.5 – 9.5)$	7.57(4.99-10.76)	11.51(8.38-14.70)		14.65(8.51-21.75)	
Increased	44(81.48%)	93(92.08%)		88(87.13%)	
Decreased	3(6.82%)	1(1%)		4(3.96%)	
Neutrophils (×10 $\square$ per L; normal range 1·8–6·3)	6.41(4.30-9.68)	10.64(7.57-13.21)		13.81(6.922-20.45	5)
Increased	24(4.44%)	79(78.22%)		74(73.27%)	
Decreased	3(5.56%)	1(1%)		3(2.97%)	
$Lymphocytes (\times 10 \square  per  L; normal  range  1 \cdot 1 - 3 \cdot 2)$	0.59(0.43-0.90)	0.53(0.33-0.66)		0.61(0.37-1.02)	
Decreased	47(87.04%)	94(93.07%)		82(81.19%)	

Eosnophils	0(0-0.01)	0(0-0.02)	0.1(0-0.05)
Platelets (×10 $\square$ per L; normal range 125·0–350·0)	167.50(126.0-210.75)	161.50(116.25-226.00)	74.50(45.00-133.00)
Decreased	12(22.22%)	29(28.71%)	65(64.36%)
Coagulation function			
Prothrombin time (s; normal range 10·5–13·5)	11.80(10.9-12.93)	12.55(11.60-14.10)	19.25(14.15-27.55)
Increased	3(5.56%)	28(27.72%)	67(66.34%)
D-dimer (µg/L; normal range 0·0–1·5)	1.51(0.80-7.18)	15.93(2.37-40.65)	25.29(7.93-71.15)
Increased	23(42.59%)	74(73.27%)	71(70.30%)
Liver function			
ALT(U/L; normal range 7-40)	32.00(20-48)	42(21.75-67)	36(19-94)
Increased	19(35.19%)	50(49.50%)	44(43.56%)
AST(U/L; normal range 13–35)	38(32-59)	47(33.75-66.25)	59(34-223)
Increased	32(59.26%)	68(67.33%)	67(66.33%)
Total bilirubin (μmol/L; normal range 0·0–21·0)	12.60(10.60-18.60)	17.60(11.55-24.40)	20.20(11.75-33.425)
Increased	8(14.81%)	31(30.69%)	43(42.57%)
Renal function			
Serum creatinine (µmol/L; normal range	74.40(64-94.30)	74.95(61.80-101.43)	173.70(96.60-350.70)
57–111)			
Increased	7(12.96%)	15(14.85%)	62(61.39%)
Blood urea nitrogen (mmol/L; normal range	6.0(4.8-7.6)	8.1(6.5-10.43)	15.80(9.4-24.3)
3-6-9-5)			

Sodium level( mmol/L;normal range 137-147)	139(136-141)	140(138-142.50)	144(140-149)
Potassium level( mmol/L;normal range 3.5-5.3)	4.2(3.7-4.5)	4(3.55-4.6)	4.4(3.8-5.0)
Cardiac function			
hsTroponin I((U/L; normal range 0-10)	16.55(10.08-40.80)	45.65(9.98-253.18)	361.35(95.48-2156.53)
Increased	12(24.07%)	51(50.50%)	73(72.28%)
BNP(pg/mL; normal range 0·0–100)	61.90(21.2-156.7)	104.3(50.33-197.38)	501.80(83.75-1259.15)
Increased	9(16.67%)	37(36.63%)	41(40.59%)
CK-MB (U/L; normal range 0-24)	17(14.75-22.00)	20(15-27.50)	32.50(18.75-77.75)
Increased	9(16.67%)	32(31.68%)	56(55.45%)
Striated muscle function			
Creatine kinase (U/L; normal range 50·0–310·0)	106(62.75-220.5)	111(59-273.50)	260(133-1055.5)
Increased	6(11.11%)	21(20.79%)	37(36.63%)
LDH((U/L; normal range 120-250)	449(315.50-612.25)	556(436.25-709.75)	727.50(485.75-1728.50)
increased	41(75.93%)	91(90.10%)	82(81.19%)
Myoglobin (ng/mL; normal range 0·0–146·9)	96(56.95-168.45)	111.60(64.90-270.85)	1132.25(331.85-1200)
Increased	13(24.07%)	38(37.62%)	66(65.35%)
Infection-related biomarkers			
Procalcitonin (ng/mL; normal range 0-0.5 )	0.075(0.05-0.235)	0.23(0.08-0.70)	2.58(0.92-6.95)
Increased	4(7.41%)	29(28.71%)	64(63.37%)
C-reactive protein (mg/L; normal range 0·0–5·0)	118.15(74.95-160)	141.80(73-160)	160(99.68-160)

Interleukin-6 (pg/mL; normal range 0·0-7·0)	9.14(7.03-13.11)	9.7(7.50-20.56)	26.21(11.68-205.92)
Increased	29(53.7%)	59(58.42%)	51(50.50%)
SSA((mg/L; normal range 0-10)	196.70(172.15-224.775)	204.30(165.90-261.20)	216.90(167.45-276.15)

Values are numbers (percentages) or Medium (IQR) unless stated otherwise. Percentages do not total 100% owing to missing data.

Table4.The course of COVID-19,grouped by serum hsTroponin I at admission to general ward

	Increased group(N=12)	Normal group(N=28)	P value
Days from onset to admission	12(10.25-12.75)	10(8-12.75)	0.213
Days from admission to ICU	1.095(1-3.75)	6(3-10)	0.000
Days in ICU	4(2-8.75)	5(2-9)	0.652
Days from onset to death	18.5(14.5-21.14)	22.5(19-29.75)	0.016

Values are Medium (IQR) unless stated otherwise. P values indicate differences between increased group of hsTroponin I and normal group patients. P < .05 was considered statistically significant

Table5.The course of COVID-19,grouped by serum hsTroponin I at admission to ICU

	Increased group(N=51)	Normal group(N=35)	P value
Days from onset to admission	11(8-15)	12 ( 8-13 )	0.059
Days from admission to ICU	0(0-3)	3(1-10)	0.640
Days in ICU	7(4-10)	4(1-8)	0.014
Days from onset to death	20(15-27)	21(17-29)	0.055

Values are Medium (IQR) unless stated otherwise.

P values indicate differences between increased group of hsTroponin I and normal group patients.

P < .05 was considered statistically significant

Figure 1. Dynamic Profile of Laboratory Parameters in 101 Patients With COVID-19




Fig.1 Timeline charts illustrate the laboratory parameters in 101 patients with COVID-19 when their entrance into admission, ICU and 48 h before death. \*P < .05 vs. At admission group, #P < .05 vs. Admission to ICU group.

## Reference

- Wuhan Municipal Health Commission. Report of clustering pneumonia of unknown etiology in Wuhan City.December 31,2019.
  http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989
- WHO. Novel coronavirus China.Jan 12, 2020.
  http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
- 3. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med* 2020.DOI:10.1056/NEJMoa2001191.
- WHO.Novel coronavirus Japan (ex-China). Jan 17, 2020.
  http://www.who.int/csr/don/17-january-2020-novel-coronavirusjapan-ex-china/en/
- WHO.Coronavirus disease 2019 (COVID-19) Situation Report–45.March 5,2020.
  https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200305-sit
  rep-45-covid-19.pdf?sfvrsn=ed2ba78b 2
- 6. WHO.Novel Coronavirus(2019-nCoV) Situation Report-11.January 31,2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sit rep-11-ncov.pdf?sfvrsn=de7c0f7\_4
- 7. WHO.Novel Coronavirus(2019-nCoV) Situation Report–22.February 11,2020.https://www.who.int/docs/default-source/coronaviruse/situation-reports/202 00211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1\_2
- 8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395: 497–506.

- 9. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; 395: 507–513.
- 10. Wang D,Hu B,Hu C.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; published online Feb 7.
- 11. National Health Commission of the People's Republic of China.COVID-19 's diagnosis and treatment Plan (trial Fifth Edition).http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1 e3e13a.shtml
- 12. Xu Pu,Xiong Yan,Cao Kejie.Distribution of ABO and RhD blood group among healthy Han population in Wuhan[J].J Clin Hematol(China) 2015;28(10):835-837.
- 13. Anstee DJ.The relationship between blood groups and disease[J].Blood 2010;115(23):4635-4643.
- 14. Tre 'goue't D-A,Heath S,Saut N,et al.Common susceptibility alleles are unlikely to contribute as strongly as the *FV* and *ABO* loci to VTE risk: results from a GWAS approach[J]. *Blood* 2009;113(21):5298-5303.
- 15. Rich SM,Leendertz F,Xu G,et al.The origin of malignant malaria[J].*Proc Natl Acad Sci U S A*,2009,106(35):14902-14907.
- 16. Cheng Y, Cheng G, Chui CH,et al.ABO blood group and susceptibility to severe

acute respiratory syndrome[J]. JAMA 2005;293:1450-1451.

- 17. Guillon P, Clément M, Sébille V,et al.Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies[J]. Glycobiology 2008;18(12):1085-1093.
- 18. Yang X, Yu Y, Xu J,et al.Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J].Lancet Respir Med,2020.Published online February 21.
- 19. Zhou P, Yang XL, Wang XGet al.A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020. Published online February 3.